White Paper

New Opportunities For Immuno-oncology Clinical Development Programs Through T Cell/B Cell Repertoire Profiling

Source: Q2 Solutions

Victor Weigman, Ph.D., Associate Director, Translational Genomics; Patrick Hurban, Ph.D., Scientific Advisor, Genomics; Senior Director and Global Head, Translational Genomics; Alan Wookey, B.Sc., Scientific Advisor, Oncology; and Patrice Hugo, Ph.D., Chief Scientific Officer - Q2 Solutions

New Opportunities For Immuno-oncology Clinical Development Programs

To better predict patients likely to respond to immuno-therapeutics, biomarker evaluation has expanded to the use of molecular analysis and has evolved from a focus on single analyte biomarker testing to multiplex analysis, wherein multiple genes to whole exomes can be assessed.

Today, a variety of treatment modalities targeting the immune system require tailored broad-spectrum biomarker screening to characterize mutational changes and the effects they have on the ability of T cells to mount immune responses to tumor antigens. Learn more about immune repertoire sequencing and how understanding a patient's immune profile can benefit for your clinical development program.